Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Increased dopamine transmission in schizophrenia: relationship to illness phases.

Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R.

Biol Psychiatry. 1999 Jul 1;46(1):56-72. Review.

PMID:
10394474
2.

Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies.

Laruelle M, Abi-Dargham A.

J Psychopharmacol. 1999 Dec;13(4):358-71. Review.

PMID:
10667612
3.

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.

Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB.

Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9235-40.

4.

Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients.

Schmitt GJ, Frodl T, Dresel S, la Fougère C, Bottlender R, Koutsouleris N, Hahn K, Möller HJ, Meisenzahl EM.

Eur Arch Psychiatry Clin Neurosci. 2006 Mar;256(2):115-21. Epub 2005 Nov 15.

PMID:
16284713
5.

Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide.

Abi-Dargham A, Kegeles LS, Zea-Ponce Y, Mawlawi O, Martinez D, Mitropoulou V, O'Flynn K, Koenigsberg HW, Van Heertum R, Cooper T, Laruelle M, Siever LJ.

Biol Psychiatry. 2004 May 15;55(10):1001-6.

PMID:
15121484
6.

Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.

Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M.

Biol Psychiatry. 2000 Oct 1;48(7):627-40.

PMID:
11032974
7.

Neurochemical brain imaging investigations of schizophrenia.

Soares JC, Innis RB.

Biol Psychiatry. 1999 Sep 1;46(5):600-15. Review.

PMID:
10472414
8.

Positron emission tomography and single photon emission CT molecular imaging in schizophrenia.

Erritzoe D, Talbot P, Frankle WG, Abi-Dargham A.

Neuroimaging Clin N Am. 2003 Nov;13(4):817-32. Review.

PMID:
15024964
9.

Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [(123)I]IBZM SPECT.

Schmitt GJ, Meisenzahl EM, Frodl T, La Fougère C, Hahn K, Möller HJ, Dresel S.

Psychiatry Res. 2009 Sep 30;173(3):183-9. doi: 10.1016/j.pscychresns.2008.11.001. Epub 2009 Aug 15.

PMID:
19683898
10.

Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT.

Laruelle M, Abi-Dargham A, van Dyck C, Gil R, D'Souza DC, Krystal J, Seibyl J, Baldwin R, Innis R.

Biol Psychiatry. 2000 Mar 1;47(5):371-9.

PMID:
10704949
11.

Imaging dopamine transmission in schizophrenia. A review and meta-analysis.

Laruelle M.

Q J Nucl Med. 1998 Sep;42(3):211-21. Review.

PMID:
9796369
12.

Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.

Mateos JJ, Lomeña F, Parellada E, Mireia F, Fernandez-Egea E, Pavia J, Prats A, Pons F, Bernardo M.

Psychopharmacology (Berl). 2007 Apr;191(3):805-11. Epub 2006 Sep 22.

PMID:
17019564
13.

Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.

Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M.

Am J Psychiatry. 1998 Jun;155(6):761-7.

PMID:
9619147
14.

The role of dopamine for the pathophysiology of schizophrenia.

Meisenzahl EM, Schmitt GJ, Scheuerecker J, Möller HJ.

Int Rev Psychiatry. 2007 Aug;19(4):337-45. Review.

PMID:
17671867
15.

[The dopamine hypothesis of schizophrenia. New findings for an old theory].

Heinz A.

Nervenarzt. 2000 Jan;71(1):54-7. Review. German.

PMID:
10695033
16.

Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects.

Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M.

Biol Psychiatry. 2009 Jun 15;65(12):1091-3. doi: 10.1016/j.biopsych.2008.12.007. Epub 2009 Jan 23.

PMID:
19167701
17.

The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]TRODAT-1.

Schmitt GJ, Meisenzahl EM, Frodl T, La Fougère C, Hahn K, Möller HJ, Dresel S.

J Psychopharmacol. 2005 Sep;19(5):488-93.

PMID:
16166186
18.

Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.

Frankle WG, Gil R, Hackett E, Mawlawi O, Zea-Ponce Y, Zhu Z, Kochan LD, Cangiano C, Slifstein M, Gorman JM, Laruelle M, Abi-Dargham A.

Psychopharmacology (Berl). 2004 Oct;175(4):473-80.

PMID:
15083259
19.

Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M.

Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8104-9.

20.

Neuroreceptor imaging in psychiatric disorders.

Frankle WG, Laruelle M.

Ann Nucl Med. 2002 Nov;16(7):437-46. Review.

PMID:
12508833
Items per page

Supplemental Content

Write to the Help Desk